Long-term unsupervised mobility assessment in movement disorders

Elke Warmerdam, Jeffrey M. Hausdorff*, Arash Atrsaei, Yuhan Zhou, Anat Mirelman, Kamiar Aminian, Alberto J. Espay, Clint Hansen, Luc J.W. Evers, Andreas Keller, Claudine Lamoth, Andrea Pilotto, Lynn Rochester, Gerhard Schmidt, Bastiaan R. Bloem, Walter Maetzler

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Mobile health technologies (wearable, portable, body-fixed sensors, or domestic-integrated devices) that quantify mobility in unsupervised, daily living environments are emerging as complementary clinical assessments. Data collected in these ecologically valid, patient-relevant settings can overcome limitations of conventional clinical assessments, as they capture fluctuating and rare events. These data could support clinical decision making and could also serve as outcomes in clinical trials. However, studies that directly compared assessments made in unsupervised and supervised (eg, in the laboratory or hospital) settings point to large disparities, even in the same parameters of mobility. These differences appear to be affected by psychological, physiological, cognitive, environmental, and technical factors, and by the types of mobilities and diagnoses assessed. To facilitate the successful adaptation of the unsupervised assessment of mobility into clinical practice and clinical trials, clinicians and researchers should consider these disparities and the multiple factors that contribute to them.

Original languageEnglish
Pages (from-to)462-470
Number of pages9
JournalThe Lancet Neurology
Issue number5
StatePublished - May 2020


FundersFunder number
Biogen Biotechnologies
Data Science Support Programme University of Groningen
EU's H2020 research and innovation programme
EU's Horizon 2020
German Federal Ministry of Education of Research
International Society for the Measurement of Physical Behavior
Italian Movement Disorder Society
Lausanne Orthopedics Research Foundation
MDS Technology Task Force
Michael J Fox Foundation for Parkinson's Research and Schaller-Nikolich Foundation
Nutricia Pharmaceuticals
Osmotica Pharmaceutical
Pierre Mercier Foundation
Stichting Parkinson Fonds
Swiss Federal Office of Sport
Swiss National Science
Topconsortium voor Kennis en Innovatie Life Sciences and Health
Topsector Life Sciences and Health
Université Grenobles Aples
Zambon Pharmaceuticals
National Institutes of Health
Michael J. Fox Foundation for Parkinson's Research
American Academy of Neurology
GE Healthcare
Chiesi Farmaceutici
International Parkinson and Movement Disorder Society
BioMarin Pharmaceutical
Horizon 2020 Framework Programme820820
H2020 Marie Skłodowska-Curie Actions721577
Seventh Framework Programme
Sixth Framework Programme
Parkinson's Foundation
European Federation of Pharmaceutical Industries and Associations
ACADIA Pharmaceuticals
Acorda Therapeutics
UCB Pharma
Philips Research Americas
Great Lakes Neurotechnologies
Verily Life Sciences
Medical Research Council
National Institute for Health and Care Research
Parkinson's UK
Stroke Association
European CommissionH2020
Health Research Council of New Zealand
Robert Bosch Stiftung
Deutsche Forschungsgemeinschaft
United States-Israel Binational Science Foundation
Kommission für Technologie und Innovation
Nederlandse Organisatie voor Wetenschappelijk Onderzoek
Israel Science Foundation
Schweizerische Herzstiftung
Österreichische Forschungsförderungsgesellschaft
Ministry of Science and Technology, Israel
Schweizerische Multiple Sklerose Gesellschaft
Hanzehogeschool Groningen
Innovative Medicines Initiative
H. Lundbeck A/S
Innosuisse - Schweizerische Agentur für Innovationsförderung
Samenwerkingsverband Noord-Nederland


    Dive into the research topics of 'Long-term unsupervised mobility assessment in movement disorders'. Together they form a unique fingerprint.

    Cite this